title: Medication effects on one-carbon metabolism in schizophrenia, mania, and major depression.
abstract: Erythrocyte methionine adenosyltransferase (MAT) activity (Vmax) and phosphatidylcholine (PC) levels previously have been found increased in manic patients and decreased in depressive and schizophrenic patients. To evaluate whether these abnormalities were the result of medication effects, erythrocyte MAT activity (Vmax) was assayed for paired samples from 29 schizophrenic, 16 manic, and 12 depressive patients, an erythrocyte PC levels were obtained for paired samples from 13 schizophrenic, seven manic, and seven depressive patients. Patients were medication free for at least 3 weeks. Vmax was significantly increased in schizophrenic and depressive patients (p less than 0.01; p less than 0.01) and significantly decreased (p less than 0.01) in manic patients after 2 weeks of psychotropic medication. Similar trends were found in PC levels. The findings of those one-carbon metabolism tests following medication are generally opposite to those reported to be related to specific disorders and tend toward normalization. Moreover, in vitro preincubation of erythrocytes of three normal subjects with the most commonly used neuroleptics had no consistent effects of MAT Vmax. These findings confirm previous studies that showed similarities in one-carbon metabolism of schizophrenic and depressed patients as opposed to manic patients and suggest that medications tend to correct or minimize rather than induce such abnormalities.
authors.forename: D A
authors.initials: DA
authors.lastname: Morere
authors.forename: R D
authors.initials: RD
authors.lastname: Alarcon
authors.forename: J A
authors.initials: JA
authors.lastname: Monti
authors.forename: W G
authors.initials: WG
authors.lastname: Walter-Ryan
authors.forename: A J
authors.initials: AJ
authors.lastname: Bancroft
authors.forename: J R
authors.initials: JR
authors.lastname: Smythies
authors.forename: L C
authors.initials: LC
authors.lastname: Tolbert
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000378:metabolism*; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008716:Methionine Adenosyltransferase / Q000097:blood*; D008745:Methylation; D010713:Phosphatidylcholines / Q000097:blood*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*; D014166:Transferases / Q000097:blood*
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D010713:Phosphatidylcholines; D008094:Lithium; D014166:Transferases; D008716:Methionine Adenosyltransferase